Filing Details

Accession Number:
0001209191-23-013004
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-24 20:34:17
Reporting Period:
2023-02-23
Accepted Time:
2023-02-24 20:34:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1706431 Vir Biotechnology Inc. VIR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202102 A George Scangos C/O Vir Biotechnology, Inc.
499 Illinois Street, Suite 500
San Francisco CA 94158
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-23 12,631 $25.97 183,608 No 4 S Direct
Common Stock Disposition 2023-02-24 4,239 $22.74 179,369 No 4 S Direct
Common Stock Disposition 2023-02-24 10,880 $23.56 168,489 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,533,629 Indirect See footnote
Common Stock 179,930 Indirect See footnote
Common Stock 111,644 Indirect See footnote
Common Stock 827,151 Indirect See footnote
Common Stock 111,644 Indirect See footnote
Common Stock 827,151 Indirect See footnote
Footnotes
  1. Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
  2. Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.195 to $23.160 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.215 to $24.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.
  6. The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.
  7. The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
  8. The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
  9. The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.
  10. The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.